# STTK catalysts: Shattuck Labs, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sttk/catalysts

> Shattuck Labs, Inc. (STTK) has 6 upcoming catalysts. The next is the SL-846 trial start, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for STTK?

Shattuck Labs, Inc. (STTK) has 6 upcoming catalysts. The next is the SL-846 trial start, 2027. Press release filed with the SEC (EX-99): "•Shattuck expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027." [Calendar and source filings](https://sec-api.dev/companies/sttk/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-070613, https://www.sec.gov/Archives/edgar/data/1680367/000162828026070613/sttk_3q2026earningsrelease.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/sttk/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Shattuck Labs, Inc. |
| Ticker | STTK (Nasdaq) |
| SEC CIK | 1680367 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sttk |

## Cash runway

Cash $61.8M as of 2026-09-30; quarterly burn $17.5M; about 10.6 months of runway at that rate (XBRL company facts, accession 0001628280-26-070618).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 14, 2024 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036724000050/sttk_q32024earningsrelease.htm)) |
| March 27, 2025 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000009/sttk_ye2024earningsrelease.htm)) |
| May 1, 2025 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000030/sttk_q12025earningspr.htm)) |
| Q3 2025 | [SL-325 trial start](https://sec-api.dev/pdufa/sl-325) | STTK |  | scheduled | "Subject to regulatory alignment, dosing of the first participant in the single-ascending dose (SAD) portion of the trial is expected in the third quarter of 2025, and the multiple-ascending dose (MAD) portion of the trial is expected to commence in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk_2q2025earningsrelease.htm)) |
| August 14, 2025 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk_2q2025earningsrelease.htm)) |
| November 6, 2025 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000056/sttk_3q2025earningsrelease.htm)) |
| March 5, 2026 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/sttk_ye2025earningsrelease.htm)) |
| Q2 2026 | [SL-325 trial start](https://sec-api.dev/pdufa/sl-325) | STTK |  | scheduled | ""We expect to begin enrollment in our Phase 1 clinical trial, subject to regulatory alignment, in healthy volunteers later this quarter, and to complete the trial during the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk_2q2025earningsrelease.htm)) |
| May 7, 2026 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026031643/sttk_q12026earningspr.htm)) |
| August 11, 2026 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/sttk_2q2026earningsrelease.htm)) |
| Q4 2026 | [SL-325 trial start](https://sec-api.dev/pdufa/sl-325) | STTK | moderate to severe hidradenitis suppurativa, with trial initiation | scheduled | "•Announced plans to initiate the RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in patients with moderate to severe hidradenitis suppurativa, with trial initiation expected in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026070613/sttk_3q2026earningsrelease.htm)) |
| November 5, 2026 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026070613/sttk_3q2026earningsrelease.htm)) |
| 2027 | [SL-846 trial start](https://sec-api.dev/pdufa/sl-846) | STTK |  | scheduled | "•Shattuck expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026070613/sttk_3q2026earningsrelease.htm)) |
| 2027 | [SL-846 interim data readout](https://sec-api.dev/pdufa/sl-846) | STTK |  | scheduled | "•Shattuck expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026070613/sttk_3q2026earningsrelease.htm)) |
| February 2028 | [SL-325 primary completion](https://sec-api.dev/pdufa/sl-325) | STTK | Hidradenitis Suppurativa (HS) | scheduled | "NCT07934017 (A Study of SL-325 in Participants With Hidradenitis Suppurativa): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07934017)) |
| Feb to May 2028 | [SL-325 topline data readout](https://sec-api.dev/pdufa/sl-325) | STTK | Hidradenitis Suppurativa (HS) | scheduled | "NCT07934017 (A Study of SL-325 in Participants With Hidradenitis Suppurativa): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07934017)) |
| July 2028 | [SL-325 primary completion](https://sec-api.dev/pdufa/sl-325) | STTK | Crohn's Disease | scheduled | "NCT07753850 (A Study of SL-325 in Crohn's Disease Patients): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07753850)) |
| Jul to Oct 2028 | [SL-325 topline data readout](https://sec-api.dev/pdufa/sl-325) | STTK | Crohn's Disease | scheduled | "NCT07753850 (A Study of SL-325 in Crohn's Disease Patients): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07753850)) |

## Drugs

- [SL-325](https://sec-api.dev/pdufa/sl-325): crohn's disease, moderate to severe hidradenitis suppurativa, with trial initiation, Hidradenitis Suppurativa (HS)
- [SL-846](https://sec-api.dev/pdufa/sl-846): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sttk/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "STTK catalysts: Shattuck Labs, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sttk/catalysts

```bibtex
@misc{secapidev_companies_sttk_catalysts_20261116,
  title        = {STTK catalysts: Shattuck Labs, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sttk/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sttk_catalysts_20261116","title":"STTK catalysts: Shattuck Labs, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sttk/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
